

10/040244

(PW FORM PAT-1449) Patent and Trademark Office									
				021286-0272501					
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Applicant: Force, W., et al.					
				Appn. No.: 10/040,244					
				Filing Date: October 26, 2001					
Date: September 30 2003		Page	1	of	2				
						Examiner: NYA			
						Group Art Unit: 1644			
<b>U.S. PATENT DOCUMENTS</b>									
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)			Class	Sub Class	Filing Date (if appropriate)	
MJ	AR 5,677,165	10/1997	de Boer, et al.					05/28/93	
	BR 5,786,456	07/1998	Ledbetter, et al.			530	388.73	09/20/93	
	CR 5,801,227	09/1998	Fanslow, III, et al.					09/08/95	
	DR 5,874,082	02/1999	de Boer, et al.,					02/23/96	
	ER 6,004,552	12/1999	de Boer, et al.			424	144.1	06/05/95	
	FR 6,051,228	04/2000	Aruffo, et al.			424	144.1	02/19/98	
RL	GR 6,150,584	11/2000	Kucherlapati, et al.						
	HR								
	IR								
	JR								
<b>FOREIGN PATENT DOCUMENTS</b>						English Abstract	Translation Readily Available		
	Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No	Enclose	No
MJ	KR WO 99/42075	08/26/99	PCT						
	LR WO 01/83755 A2	11/2001	PCT	Mikayama, T., et al.	C12N 15/13				
	MR WO 01/83755 A3	11/2001	PCT	Mikayama, T., et al.	C12N 15/13				
MJ	NR WO 02/28904 A2	04/2002	PCT	Chu, K., et al.	C07K 16/28				
	OR								
	PR								
	QR								
	RR								
	SR								
	TR								
<b>OTHER</b> (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)									
MJ	UR	Stamenkovic, et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas", <u>The EMBO Journal</u> , (1989), No. 5, pp. 1403-1410,							
MJ	VR	Clark, et al., "CDw40 and BLCA-specific monoclonal antibodies detect two distinct molecules which transmit progression signals to human B lymphocytes", <u>Eur. J. Immunol.</u> , (1988), Vol. 18, 451-457.							


Pfleiderer

1/24/05

WR	Ledbetter, et al., "Augmentation of Normal and Malignant B Cell Proliferation by Monoclonal Antibody to the B Cell-Specific Antigen BP50 (CDW40)", <u>The Journal of Immunology</u> , (Feb. 1, 1987), Vol. 138, No. 3, pp. 788-794.			
XR	Clark, et al., "Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50", <u>Proc. Natl. Acad. Sci. USA</u> , (June 1986), Vol. 83, pp. 4494-4498.			
YR	Paulie, et al., "A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes", <u>Cancer Immunology Immunother.</u> , (1985), Vol. 20, pp. 23-28.			
Examiner		Date Considered:		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.				

Philip Gamber 1/24/05

FORM PTO-1449 (modified)  
 To: U.S. Department of Commerce  
 (PW FORM PAT-1449)  
 Patent and Trademark Office



Atty.  
 Dkt. No.

Inv#  
 10/040244  
 021286-0272501

Client Ref.

**INFORMATION DISCLOSURE STATEMENT  
 BY APPLICANT**

Date: March 20, 2003

Page 1 of 3

Applicant: Force, W., et al.

Appln. No.: 10/040,244

Filing Date: October 26, 2001

Examiner: NYA

Group Art Unit: 1644

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available	Enclosed	No	Enclose	No
CR	WO 91/09115	06/1991	PCT	Banchereau		Y				
DR	WO 96/33735	10/1996	PCT	Kucherlapati		Y				
ER	WO 96/34096	10/1996	PCT	Kucherlapati		Y				
FR	WO 99/61051	12/1999	PCT	Segal		Y				
GR	WO 00/00156	01/2000	PCT	Wade		Y				
HR	WO 00/75348 A1	12/2000	PCT	Sieggall		Y				
IR	WO 01/24823	04/2001	PCT	Keting		Y				
JR	WO 01/56603	08/2001	PCT	Thomas		Y				
KR	WO 02/28904	04/2002	PCT	Chu		Y				
LR	EP 0945 465 A1	09/1999	EP	De Boer		Y				
MR	EP 0972 445 A1	01/2000	EP	Tomizuka		Y				

**OTHER (including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

NR	Kwekkeboom, et al., "Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction," <i>Eur. J. Immunol.</i> (1994), Vol. 24, pp. 508-517.	Y
OR	Hasbold, et al., "Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4," <i>Eur. J. Immunol.</i> (1998), Vol. 28, pp. 1040-1051.	Y
PR	Pound, et al., "Minimal cross-linking and epitope requirements for D40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells," <i>Int'l Immunol.</i> (1999), Vol. 11, No. 1, pp. 11-20.	Y
QR	Francisco, et al., "Agonistic Properties and <i>in Vivo</i> Antitumor of the Anti-CD40 Antibody SGN-14," <i>Cancer Research</i> , (June 15, 2000), Vol. 60, pp. 3225-3231.	Y
RR	Romano, et al., "Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells," <i>Blood</i> , (August 1, 1998) Vol. 98, No. 3, pp. 990-995.	Y
SR	Hirano, et al., "Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand," <i>Blood</i> , (May 1, 1999), Vol. 93, No. 9, pp. 2999-3007.	Y

Philip Amode 1/24/05

1 P 14 1997 MAR 24 1997 PATENT & TRADEMARK OFFICE U.S. GOVERNMENT	TR	Francisco, et al., "Construction, Expression, and Characterization of BD1-G28-5 sFv, a Single-chain Anti-CD40 Immunotoxin Containing the Ribosome -inactivating Protein Bryodin 1," <u>Journal of Biological Chemistry</u> , (Sept. 26, 1997), Vol. 272, No. 39, pp. 24165-24169.	Y		
	UR	Maxwell, et al., "Contrasting the Roles of Costimulation and the Natural Adjuvant Lipopolysaccharide During the Induction of T Cell Immunity," <u>J. Immunol.</u> , (May 1, 2002), Vol. 168, No. 9, pp. 4372-4381.	Y		
	VR	Simonsson, et al., "Single, Antigen-Specific B Cells Used to Generate Fab Fragments Using CD40-Mediated Amplification or Direct PCR Cloning," <u>BioTechniques</u> , (1995), Vol. 18, No. 5, pp. 862-869.		TECH CENTER 1000/2800	MAR 25 2003
	WR	Dullforce, et al., "Enhancement of T cell-independent immune responses <i>in vivo</i> by CD 40 antibodies," <u>Nature Medicine</u> , (Jan. 1998), Vol. 4, No. 1, pp.88 - 91.			
	XR	Erickson, et al., "Short-circuiting long-lived humoral immunity by the heightened engagement of CD40," <u>The J. of Clinical Investigation</u> , (March, 2002), Vol. 109, No. 5, pp. 613-620.			
	YR	Murphy, et al., "Antibodies to CD40 Prevent Epstein-Barr Virus- Mediated Human B-Cell Lymphomagenesis in Severe Combined Immune Deficient Mice Given Human Peripheral Blood Lymphocytes," <u>Blood</u> , (September 1, 1995), Vol. 86, No. 5, pp. 1946-1953.			
	ZR	Funakoshi, et al., "Differential In Vitro and In Vivo Antitumor Effects Mediated by Anit-CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-Cell Lymphomas," <u>J. of Immunology</u> , (1996) Vol. 19, No. 2, pp. 93-101.	Y		
	AAR	Schwabe, et al., "Modulation of Soluble CD40 Ligand Bioactivity with Anti-CD40 Antibodies," <u>Hybridoma</u> , (1997), Vol. 16, No. 13, pp. 217-226.	Y		
	BBR	Funakoshi, et al., "Inhibition of Human B-Cell Lymphoma Growth by CD40 Stimulation," <u>Blood</u> , (May 15, 1994), Vol. 83, No. 10, pp. 2787-2794.	Y		
	CCR	Rolink, et al., "The SCID but Not the RAG-2 Gene Product Is Required for Sp-S $\epsilon$ Heavy Chain Class Switching," <u>Immunity</u> , (October, 1996) Vol. 5, pp. 319-330.	Y		
	DDR	Kwekkeboom, et al., "CD40 plays and essential role in the activation of human B cells by murine EL4B5 cells," <u>Immunology</u> , (1993), Vol. 79, pp. 439-444.	Y		
	EER	Zhou, et al., "An Agonist Anti-Human CD40 Monoclonal Antibody that Induces Dendritic Cell Formation and Maturation and Inhibits Proliferation of a Myeloma Cell Line," <u>Hybridoma</u> , Vol. 18, No. 6, 1999, pp. 471-478.	Y		
	FFR	Heath, et al., "Monoclonal antibodies to murine CD40 define two distinct functional epitopes," <u>Eur. J. Immunology</u> , (1994) Vol. 24, pp. 1828-1834.	Y		
	GGR	Mazzei, et al., "Recombinant Soluble Trimeric CD40 Ligand Is Biologically Active," <u>Journal of Biological Chemistry</u> , (March 31, 1995), Vol. 270, No. 13, pp. 7025-7028.	Y		
	HHR	Hasbold, et al., "Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies," <u>Eur. J. Immunology</u> , (1994) Vol. 24, pp. 1835-1842.	Y		
	IIR	Weng, et al., "Human Anti-CD40 Antagonistic Antibodies Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma," Program of the 43 <sup>rd</sup> Annual Meeting of The American Society of Hematology, (December 7-11, 2001), Abstract No. 1947, page 466a.	Y		
	JJR	Ledbetter, et al., "Agonistic Activity of a CD40-Specific Single-Chain Fv Constructed from the Variable Regions of mAb G28-5," <u>Critical Reviews in Immunology</u> , (1997), Vol. 17, pp. 427-435.	Y		
	KKR	de Boer, et al., "Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins," <u>Journal of Immunological Methods</u> , (1992) Vol. 152, pp. 15-23.	Y		
	LLR	Karlsson, et al., "Selection of human single chain antibodies against CD-40," <u>Immunology Letters</u> , Vol. 73, Nos. 2,3, Abstract No. 358.	Y		
	MMR	Sotomayor, et al., "Conversion of tumor-specific CD4 T-cell tolerance to T-cell priming through <i>in vivo</i> ligation of CD40," <u>Nature</u> , (July, 1999), Vol. 399, No. 7, pp. 780-787.	Y		

MAR 25 2003  
PATENT & TRADEMARK OFFICE

NNR	Diehl, et al., "CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy," <u>Nature Medicine</u> , (July 1999) Vol. 5, No. 7, pp. 774-779.	Y		
QOR	Schoenberger, et al., "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions," <u>Nature</u> , (June 4, 1998), Vol. 393, pp. 480-483.	Y		
PPR	van Mierlo, et al. "CD40 stimulation leads to effective therapy of CD40-tumors through induction of strong systemic cytotoxic T lymphocyte immunity," <u>PNAS</u> , (April 16, 2002) Vol. 99, No. 8, pp. 5561-5566.	Y		
QQR	An, et al., "Ligation of CD40 Potentiates Fas-Mediated Activation of the Cysteine Protease CPP32, Cleavage of Its Death Substrate PARP, and Apoptosis in Ramos - Burkitt Lymphoma B Cells," <u>Cellular Immunology</u> , (1997) Vol. 181, pp. 139-152.	Y		
RRR	Barr, et al., "Functional activity of CD40 antibodies correlates to the position of binding relative to CD154," <u>Immunology</u> , (2001) Vol. 102, pp. 39-43.	Y		
SSR	Baccam, et al., "Membrane-bound CD154, but not CD40-specific antibody, mediates NF- $\kappa$ B-independent IL-6 production in B cells," <u>Br. J. Immunol.</u> , (1999), Vol. 29, pp. 3855-3866.	Y		
TTR	Kedl, et al., "CD40 stimulation accelerates deletion of tumor specific CD8+ T cells in the absence of tumor-antigen vaccination," <u>PNAS</u> , (September 11, 2001) Vol. 98, No. 19, pp. 10811-10816.	Y		
UUR	Tomizuka, et al., "Double trans-chromosomal mice: Maintenance of two individual human chromosome fragments containing Ig heavy and $k$ loci and expression of fully human antibodies," <u>PNAS</u> , (January 18, 2000) Vol. 97, No. 2, pp. 722-727.	Y		
VVR	Boon, et al., "Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys," <u>Toxicology</u> , (2002), Vol. 174, pp. 53-65.	Y		
WWR				
XXR				
YYR				
ZZR				
Examiner	Date Considered:			

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED  
MAR 25 2003  
TECH CENTER 1600/2900

Philip GMB  
1/24/05